Three-dimensional flow-through protein platform.

Area of Science:

• Biotechnology
• Analytical Chemistry
• Biomedical Engineering

Background:

• Conventional protein microarrays often face limitations in binding efficiency and assay time.
• There is a need for rapid, sensitive, and low-volume diagnostic platforms for clinical settings.

Purpose of the Study:

• To develop and validate a novel protein microarray platform, the ImmunoFlow Protein Platform (IFPP), for enhanced protein detection.
• To demonstrate the IFPP's capability for rapid and sensitive quantification of biomarkers like C-reactive protein (CRP).

Main Methods:

• Development of a protein microarray utilizing a porous nitrocellulose membrane with active sample pumping.
• Assay optimization to enhance binding kinetics and stringency compared to traditional methods.
• Validation of CRP detection in human plasma and serum against standard clinical laboratory assays.

Main Results:

• The IFPP demonstrated a binding rate enhancement of at least 10-fold compared to conventional methods.
• Achieved sensitive detection of 1 picomolar (pM) C-reactive protein (CRP) in 70 microliters (µL) of plasma within 7 minutes.
• IFPP performance in CRP detection was validated against established clinical laboratory methods.

Conclusions:

• The ImmunoFlow Protein Platform significantly accelerates protein microarray assay times and enhances sensitivity.
• The IFPP's speed, sensitivity, and low sample volume requirements make it suitable for point-of-care diagnostics.
• The platform shows clinical utility for rapid biomarker detection in patient samples.